Skip to main content
Fig. 3 | BMC Biotechnology

Fig. 3

From: Immobilisation of Delta-like 1 ligand for the scalable and controlled manufacture of hematopoietic progenitor cells in a stirred bioreactor

Fig. 3

Investigating manufacturing challenges of the use of immobilised Delta-Like 1. Efficacy of the immobilisation process was evaluated using an ELISA immunoassay. a Efficacy was dependent on the number of particles generated, with up to 96% of the protein immobilised (n = 3). Removal of magnetic particles was evaluated by flow cytometry. b Voltage setting and gating was optimised to assess particle number in culture (i) and after removal from culture (ii), c removal of magnetic particles from cells at the end of the culture period was evaluated, MACS® columns removed 99.6% of particles with minimal cell loss (<1%) (n = 6)

Back to article page